Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGT NASDAQ:CTMX NASDAQ:JANX NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$12.43-1.9%$11.83$3.72▼$13.50$1.41B0.351.93 million shs520,289 shsCTMXCytomX Therapeutics$1.97-1.8%$2.20$0.40▼$3.10$324.05M2.183.21 million shs2.37 million shsJANXJanux Therapeutics$23.49-2.3%$24.58$21.97▼$71.71$1.41B2.84909,711 shs354,514 shsSNDXSyndax Pharmaceuticals$15.64+0.6%$12.90$8.58▼$22.50$1.35B0.722.22 million shs1.47 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences0.00%-2.99%+6.48%+69.03%+19.10%CTMXCytomX Therapeutics0.00%-12.28%+4.71%-18.70%+62.60%JANXJanux Therapeutics0.00%+0.29%-4.22%+1.86%-51.91%SNDXSyndax Pharmaceuticals0.00%-8.74%-1.21%+55.66%-18.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$12.43-1.9%$11.83$3.72▼$13.50$1.41B0.351.93 million shs520,289 shsCTMXCytomX Therapeutics$1.97-1.8%$2.20$0.40▼$3.10$324.05M2.183.21 million shs2.37 million shsJANXJanux Therapeutics$23.49-2.3%$24.58$21.97▼$71.71$1.41B2.84909,711 shs354,514 shsSNDXSyndax Pharmaceuticals$15.64+0.6%$12.90$8.58▼$22.50$1.35B0.722.22 million shs1.47 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences0.00%-2.99%+6.48%+69.03%+19.10%CTMXCytomX Therapeutics0.00%-12.28%+4.71%-18.70%+62.60%JANXJanux Therapeutics0.00%+0.29%-4.22%+1.86%-51.91%SNDXSyndax Pharmaceuticals0.00%-8.74%-1.21%+55.66%-18.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.92Moderate Buy$20.0060.97% UpsideCTMXCytomX Therapeutics 3.00Buy$5.75192.62% UpsideJANXJanux Therapeutics 3.07Buy$80.92244.47% UpsideSNDXSyndax Pharmaceuticals 3.00Buy$39.22150.72% UpsideCurrent Analyst Ratings BreakdownLatest CTMX, COGT, SNDX, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025JANXJanux TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$100.009/10/2025JANXJanux TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.009/10/2025SNDXSyndax PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.009/5/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.009/4/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$34.009/3/2025JANXJanux TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.009/3/2025JANXJanux TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.009/2/2025COGTCogent BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$30.008/25/2025COGTCogent BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$17.00 ➝ $20.008/18/2025JANXJanux TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$42.008/7/2025COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$29.00 ➝ $30.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/ACTMXCytomX Therapeutics$138.10M2.35$0.36 per share5.53($0.01) per share-196.50JANXJanux Therapeutics$10.59M133.29N/AN/A$19.49 per share1.21SNDXSyndax Pharmaceuticals$77.93M17.29N/AN/A$3.38 per share4.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$255.86M-$1.78N/AN/AN/AN/A-223.82%-89.44%11/11/2025 (Estimated)CTMXCytomX Therapeutics$31.87M$0.563.51N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)Latest CTMX, COGT, SNDX, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A8/5/2025Q2 2025COGTCogent Biosciences-$0.55-$0.53+$0.02-$0.53N/AN/A8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A4.194.19CTMXCytomX TherapeuticsN/A4.204.20JANXJanux TherapeuticsN/A47.0347.03SNDXSyndax Pharmaceuticals2.064.714.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/ACTMXCytomX Therapeutics67.77%JANXJanux Therapeutics75.39%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences7.29%CTMXCytomX Therapeutics6.60%JANXJanux Therapeutics29.40%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableJANXJanux Therapeutics3060.09 million42.43 millionOptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableCTMX, COGT, SNDX, and JANX HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at Stifel NicolausSeptember 12 at 9:04 AM | marketbeat.comZimmer Partners LP Buys Shares of 213,159 Syndax Pharmaceuticals, Inc. $SNDXSeptember 11, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Bought by Exome Asset Management LLCSeptember 11, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated at Stifel NicolausSeptember 11, 2025 | americanbankingnews.comInsider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 157,307 Shares of StockSeptember 10, 2025 | marketbeat.comSyndax resumed with Buy at Stifel on newly launched drugsSeptember 10, 2025 | msn.comPolar Asset Management Partners Inc. Purchases 21,630 Shares of Syndax Pharmaceuticals, Inc. $SNDXSeptember 9, 2025 | marketbeat.comStocks To Watch: Syndax Pharmaceuticals Sees Relative Strength Rating Jump To 84September 8, 2025 | msn.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $24.00September 8, 2025 | americanbankingnews.comGranahan Investment Management LLC Has $6.76 Million Stake in Syndax Pharmaceuticals, Inc. $SNDXSeptember 7, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Research Coverage Started at GuggenheimSeptember 7, 2025 | americanbankingnews.comGuggenheim Begins Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)September 6, 2025 | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.com59,210 Shares in Syndax Pharmaceuticals, Inc. $SNDX Purchased by Ieq Capital LLCSeptember 5, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comGuggenheim Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy RecommendationSeptember 4, 2025 | msn.comDeep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)September 4, 2025 | benzinga.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Palo Alto Investors LPSeptember 4, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Invesco Ltd.September 4, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Buy" by AnalystsSeptember 4, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTMX, COGT, SNDX, and JANX Company DescriptionsCogent Biosciences NASDAQ:COGT$12.42 -0.24 (-1.86%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.CytomX Therapeutics NASDAQ:CTMX$1.96 -0.04 (-1.75%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Janux Therapeutics NASDAQ:JANX$23.49 -0.56 (-2.33%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Syndax Pharmaceuticals NASDAQ:SNDX$15.64 +0.09 (+0.60%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
